Clinical Relevance of Pharmacogenetics in Serotonin Syndrome

الملخص EN

Serotonin syndrome is a predictable life-threatening condition that is caused by serotonergic stimulation of the central and peripheral nervous systems.

A patient’s genetic profile can amplify exposure risk as many serotonergic drugs are metabolized by CYP450 enzymes, and these enzymes may be altered in functionality.

We report a case of an elderly man who presented with serotonin syndrome after a dose change in valproic acid 5 weeks prior.

His medication list consisted of low-dose serotonergic agents, which is unusual as most cases of serotonin syndrome involve higher doses.

A review of his pharmacogenetic profile is presented to retrospectively evaluate the additive risk for serotonin syndrome and implications on resuming serotonergic agents.